Today: 14 May 2026
Browse Category

NASDAQ:RIGL 5 November 2025

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Rigel Pharmaceuticals shares jumped over 30% to around $38 on Nov. 5, 2025, after reporting Q3 revenue of $69.5 million, up 25% year-over-year. Net income reached $27.9 million, and the company raised its 2025 revenue guidance to $285–$290 million. Product sales, led by Tavalisse, surged 65%. Rigel also announced new clinical milestones and ongoing global partnerships.
5 November 2025
··

Stock Market Today

  • LunR Royalties (TSXV:LUNR) Soars 84.6% in 2024 Despite No Revenue, Valuation Questions Arise
    May 14, 2026, 1:18 AM EDT. LunR Royalties (TSXV:LUNR) surged 84.6% year to date, reaching a CA$24 share price and a market cap near CA$1.68 billion. Despite this rally, the company posted no revenue and a net loss of CA$0.96 million. Its price-to-book ratio stands at an extreme 430.4x, vastly exceeding the Canadian metals and mining sector average of 3.2x. This valuation implies high investor expectations for future royalty income and project success, though the lack of current earnings and large valuation gap raise concerns about potential downside if exploration or timelines falter. Investors are urged to weigh these risks carefully before committing, considering the company's momentum balanced against its unproven profitability.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 1:28 AM EDT LunR Royalties (TSXV:LUNR) Soars 84.6% in 2024 Despite No Revenue, Valuation Questions Arise May 14, 2026, 1:18 AM EDT. LunR Royalties (TSXV:LUNR) surged 84.6% year to date, reaching a CA$24 share price and a market cap near CA$1.68 billion. Despite this rally, the company posted no revenue and a net loss of CA$0.96 million. Its price-to-book ratio stands at an extreme 430.4x, vastly exceeding the Canadian metals and mining sector average of 3.2x. This valuation implies high investor expectations for future royalty income and project
Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
Go toTop